Evidence map›Paper›PMID 39475439›Full record

ArticleJournal of the National Cancer Institute2025

Supplemental breast cancer screening after negative mammography in US women with dense breasts.

Victoria M Foster, Amy Trentham-Dietz, Natasha K Stout, Christoph I Lee, Laura E Ichikawa, Joanna Eavey, Louise Henderson, Diana L Miglioretti, Anna N A Tosteson, Erin A Bowles and 2 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Victoria M FosterDepartment of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
Amy Trentham-DietzDepartment of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.ORCID 0000-0002-5971-4660
Natasha K StoutNational Cancer Institute, Rockville, MD, United States.
Christoph I LeeDepartment of Radiology, School of Medicine and Department of Health Systems & Population Health, School of Public Health, University of Washington, Seattle, WA, United States.
Laura E IchikawaKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0002-0882-6662
Joanna EaveyKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.
Louise HendersonDepartments of Radiology and Epidemiology, University of North Carolina, Chapel Hill, NC, United States.
Diana L MigliorettiKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.ORCID 0000-0002-5547-1833
Anna N A TostesonDartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.
Erin A BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.
Karla KerlikowskeDepartments of Medicine and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, United States.ORCID 0000-0001-8793-8779
Brian L SpragueUniversity of Vermont Cancer Center, University of Vermont, Burlington, VT, United States.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KARLA M KERLIKOWSKE · 2011 to 2026
$52.9M
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Robert A Koza · 2017 to 2026
$51.6M
Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2013 to 2022
$21.3M
Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum - SupplementU01CA253911 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALAGOZ, OGUZHAN, DE KONING, HARRY J · 2020 to 2025
$10.6M
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breastsR01CA248068 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Diana L Miglioretti, Brian L Sprague · 2020 to 2026
$5.1M
Breast Cancer Surveillance ConsortiumNCI NIH HHS P01 CA154292NCI NIH HHS P01CA154292NCI NIH HHS P30 CA014520NCI NIH HHS P30CA014520NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA248068NCI NIH HHS R01CA248068NCI NIH HHS U01 CA253911NCI NIH HHS U01CA253911NIGMS NIH HHS P20 GM103644NIGMS NIH HHS U54 GM115516NIGMS NIH HHS U54GM115516NIH HHS
6 · The paper itself

Abstract

The extent and determinants of supplemental screening among women with dense breasts are unclear. We evaluated a retrospective cohort of 498 855 women aged 40-74 years with heterogeneously or extremely dense breasts who obtained 1 176 251 negative screening mammography examinations during 2011-2019 in the United States. Overall, 2.8% and 0.3% of mammograms had supplemental ultrasound or magnetic resonance imaging (MRI) within 1 year, respectively. Onsite availability was associated with ultrasound (odds ratio [OR] = 4.35, 95% confidence interval [CI] = 4.21 to 4.49) but not MRI (OR = 0.94, 95% CI = 0.85 to 1.04). Facility academic affiliation and for-profit status were inversely associated with supplemental ultrasound (OR = 0.53, 95% CI = 0.49 to 0.57, and OR = 0.83, 95% CI = 0.81 to 0.86, respectively) and positively associated with supplemental MRI (OR = 3.04, 95% CI = 2.86 to 3.46, and OR = 1.88, 95% CI = 1.66 to 2.12, respectively). Supplemental screening was more likely to occur after passage of state-specific density notification laws than before passage (OR = 3.56, 95% CI = 3.30 to 3.84, and OR = 1.79, 95% CI = 1.60 to 2.00, respectively). These results show that supplemental breast imaging utilization has been uncommon and was related to facility factors and density legislation.

Indexed as

Breast DensityBreast NeoplasmsEarly Detection of CancerMammographyAdultAgedBreastFemaleHumansMagnetic Resonance ImagingMass ScreeningMiddle AgedRetrospective StudiesUnited States

Identifiers

PMID39475439
PMCPMC12145904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.